[Comment] Aldosterone Synthase Inhibition in Resistant Hypertension: Promises and Unknowns

Why It Matters

Targeting aldosterone production could overcome limitations of current fourth‑line drugs and improve control in patients who remain hypertensive despite maximal therapy, potentially reshaping treatment pathways and lowering cardiovascular event rates.

Key Takeaways

• Aldosterone synthase inhibitors lower BP in resistant hypertension
• Phase‑3 trials show baxdrostat efficacy comparable to spironolactone
• Long‑term renal safety of ASIs remains unproven
• Drug‑drug interactions may limit use with existing antihypertensives
• Guideline integration awaits further outcome data

Pulse Analysis

Resistant hypertension remains a global health challenge, affecting roughly 1.3 billion adults and accounting for a disproportionate share of cardiovascular morbidity. Standard regimens—typically three‑drug combinations—fail to achieve target pressures in about one‑fifth of patients, prompting clinicians to add mineralocorticoid receptor antagonists such as spironolactone. While effective, these agents are limited by hyperkalaemia, endocrine side effects, and variable adherence, underscoring the need for novel mechanisms that can safely deepen blood‑pressure control.

Aldosterone synthase inhibition represents a mechanistically distinct approach by blocking the enzyme responsible for aldosterone biosynthesis rather than antagonizing its receptor. Phase‑3 trials of baxdrostat and lorundrostat have reported average systolic reductions of 12‑15 mmHg in patients with uncontrolled or resistant hypertension, rivaling the efficacy of spironolactone without the classic anti‑androgenic effects. Moreover, early pharmacokinetic data suggest a lower propensity for hyperkalaemia, offering a potentially safer profile for patients with chronic kidney disease. These findings have reignited interest in positioning ASIs as the preferred fourth‑line therapy in guideline algorithms.

Despite encouraging efficacy, several unknowns temper rapid adoption. Long‑term renal outcomes remain uncharacterized, and post‑marketing surveillance will be essential to detect rare adverse events such as adrenal insufficiency or off‑target hormonal disturbances. Drug‑drug interaction studies are limited, raising concerns about concurrent use with existing antihypertensives, especially diuretics and ACE inhibitors. Regulatory bodies are likely to await robust cardiovascular outcome data before endorsing ASIs as standard care, meaning clinicians must balance immediate blood‑pressure benefits against the current evidence gap. Continued research will determine whether aldosterone synthase inhibitors can fulfill their promise and become a mainstay in the management of resistant hypertension.